• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

    18.30 +0.47 (+2.61%)
    Streaming Delayed Price Updated: 10:33 AM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 893,956
    Open 17.62
    Bid (Size) 18.29 (400)
    Ask (Size) 18.30 (300)
    Prev. Close 17.83
    Today's Range 17.62 - 18.75
    52wk Range 3.025 - 18.94
    Shares Outstanding 121,613,181
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Is Relay Therapeutics a Buy After Promising Trial Results? ↗
    Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy. 
    Via The Motley Fool

    Performance

    YTD
    +123.7%
    +123.7%
    1 Month
    +29.1%
    +29.1%
    3 Month
    +80.8%
    +80.8%
    6 Month
    +113.7%
    +113.7%
    1 Year
    +461.2%
    +461.2%

    More News

    Read More
    News headline image
    Relay Therapeutics Announces Pricing of Public Offering of Common Stock
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Relay Therapeutics Stock Popped on Wednesday ↗
    Via The Motley Fool
    Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance ↗
    Via Chartmill
    Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗
    Via Chartmill
    News headline image
    Relay Therapeutics Announces Proposed Public Offering of Common Stock
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
    Via The Motley Fool
    News headline image
    Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Relay Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
    Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
    The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
    What is the current price of Relay Therapeutics, Inc. - Common Stock?
    The current price of Relay Therapeutics, Inc. - Common Stock is 18.30
    When was Relay Therapeutics, Inc. - Common Stock last traded?
    The last trade of Relay Therapeutics, Inc. - Common Stock was at 06/26/26 10:33 AM ET
    What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
    The market capitalization of Relay Therapeutics, Inc. - Common Stock is 2.22B
    How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
    Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.